---
document_datetime: 2025-12-29 12:06:49
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pandemrix.html
document_name: pandemrix.html
version: success
processing_time: 0.1315143
conversion_datetime: 2025-12-30 01:39:30.577773
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pandemrix

[RSS](/en/individual-human-medicine.xml/65530)

##### Expired

This medicine's authorisation has expired

influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted) Medicine Human Expired

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pandemrix](#news-on)
- [More information on Pandemrix](#more-information-on-pandemrix-458)
- [More information on Pandemrix](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The marketing authorisation for the vaccine Pandemrix expired on 13 August 2015 following the decision of the marketing authorisation holder, GlaxoSmithKline Biologicals, not to apply for a renewal of the marketing authorisation. Pandemrix is a split virion, inactivated, adjuvanted pandemic influenza vaccine containing A/California/7/2009 (H1N1)v like strain (X-179A).

GlaxoSmithKline Biologicals confirmed that it did not apply for a renewal of the authorisation due to lack of demand for the vaccine. Pandemrix was granted marketing authorisation in the European Union (EU) on 12 August 2010 for prophylaxis of influenza caused by A (H1N1)v 2009 virus. The marketing authorisation was valid for 5 years.

Pandemrix was used extensively during the 2009 (H1N1)v pandemic, with over 30 million people vaccinated in the EU. Cases of narcolepsy were reported in people who had received the vaccine during the 2009 pandemic. Understanding the link between narcolepsy and Pandemrix remains the subject of investigations and may have implications for the future use of similar vaccines. Therefore, irrespective of the expiry of the marketing authorisation for Pandemrix, the marketing authorisation holder agreed with the Agency to continue to investigate narcolepsy in association with vaccination and will submit to the Agency for evaluation any relevant data generated by the company as well as independent parties.

GlaxoSmithKline Biologicals is the marketing authorisation holder for another pandemic vaccine, Adjupanrix, which is authorised in the EU for pandemic preparedness. GlaxoSmithKline Biologicals will maintain the marketing authorisation for Adjupanrix.

The European Public Assessment Report (EPAR) for Pandemrix will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Pandemrix : EPAR - Summary for the public

Reference Number: EMA/684025/2012

English (EN) (122.93 KB - PDF)

**First published:** 22/12/2009

**Last updated:** 10/06/2016

[View](/en/documents/overview/pandemrix-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-268)

български (BG) (167.25 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/bg/documents/overview/pandemrix-epar-summary-public_bg.pdf)

español (ES) (126.22 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/es/documents/overview/pandemrix-epar-summary-public_es.pdf)

čeština (CS) (143.01 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/cs/documents/overview/pandemrix-epar-summary-public_cs.pdf)

dansk (DA) (133.72 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/da/documents/overview/pandemrix-epar-summary-public_da.pdf)

Deutsch (DE) (125.39 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/de/documents/overview/pandemrix-epar-summary-public_de.pdf)

eesti keel (ET) (120.64 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/et/documents/overview/pandemrix-epar-summary-public_et.pdf)

ελληνικά (EL) (173.86 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/el/documents/overview/pandemrix-epar-summary-public_el.pdf)

français (FR) (148.75 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/fr/documents/overview/pandemrix-epar-summary-public_fr.pdf)

hrvatski (HR) (130.83 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/hr/documents/overview/pandemrix-epar-summary-public_hr.pdf)

italiano (IT) (121.53 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/it/documents/overview/pandemrix-epar-summary-public_it.pdf)

latviešu valoda (LV) (143.99 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/lv/documents/overview/pandemrix-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (176.22 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/lt/documents/overview/pandemrix-epar-summary-public_lt.pdf)

magyar (HU) (167.66 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/hu/documents/overview/pandemrix-epar-summary-public_hu.pdf)

Malti (MT) (160.07 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/mt/documents/overview/pandemrix-epar-summary-public_mt.pdf)

Nederlands (NL) (131.32 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/nl/documents/overview/pandemrix-epar-summary-public_nl.pdf)

polski (PL) (166.63 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/pl/documents/overview/pandemrix-epar-summary-public_pl.pdf)

português (PT) (127.26 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/pt/documents/overview/pandemrix-epar-summary-public_pt.pdf)

română (RO) (151.59 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/ro/documents/overview/pandemrix-epar-summary-public_ro.pdf)

slovenčina (SK) (153.08 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/sk/documents/overview/pandemrix-epar-summary-public_sk.pdf)

slovenščina (SL) (143.17 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/sl/documents/overview/pandemrix-epar-summary-public_sl.pdf)

Suomi (FI) (122.5 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/fi/documents/overview/pandemrix-epar-summary-public_fi.pdf)

svenska (SV) (136.25 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

10/06/2016

[View](/sv/documents/overview/pandemrix-epar-summary-public_sv.pdf)

## Product information

Pandemrix : EPAR - Product Information

English (EN) (1.11 MB - PDF)

**First published:** 23/12/2009

**Last updated:** 10/06/2016

[View](/en/documents/product-information/pandemrix-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-233)

български (BG) (1.58 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/bg/documents/product-information/pandemrix-epar-product-information_bg.pdf)

español (ES) (1.2 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/es/documents/product-information/pandemrix-epar-product-information_es.pdf)

čeština (CS) (1.21 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/cs/documents/product-information/pandemrix-epar-product-information_cs.pdf)

dansk (DA) (1.36 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/da/documents/product-information/pandemrix-epar-product-information_da.pdf)

Deutsch (DE) (1.2 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/de/documents/product-information/pandemrix-epar-product-information_de.pdf)

eesti keel (ET) (1.07 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/et/documents/product-information/pandemrix-epar-product-information_et.pdf)

ελληνικά (EL) (1.66 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/el/documents/product-information/pandemrix-epar-product-information_el.pdf)

français (FR) (1.09 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/fr/documents/product-information/pandemrix-epar-product-information_fr.pdf)

hrvatski (HR) (949.96 KB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/hr/documents/product-information/pandemrix-epar-product-information_hr.pdf)

íslenska (IS) (1.19 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/is/documents/product-information/pandemrix-epar-product-information_is.pdf)

italiano (IT) (1003.34 KB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/it/documents/product-information/pandemrix-epar-product-information_it.pdf)

latviešu valoda (LV) (1.08 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/lv/documents/product-information/pandemrix-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.23 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/lt/documents/product-information/pandemrix-epar-product-information_lt.pdf)

magyar (HU) (1.77 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/hu/documents/product-information/pandemrix-epar-product-information_hu.pdf)

Malti (MT) (1.37 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/mt/documents/product-information/pandemrix-epar-product-information_mt.pdf)

Nederlands (NL) (1.2 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/nl/documents/product-information/pandemrix-epar-product-information_nl.pdf)

norsk (NO) (1.21 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/no/documents/product-information/pandemrix-epar-product-information_no.pdf)

polski (PL) (1.67 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/pl/documents/product-information/pandemrix-epar-product-information_pl.pdf)

português (PT) (1.01 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/pt/documents/product-information/pandemrix-epar-product-information_pt.pdf)

română (RO) (1.3 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/ro/documents/product-information/pandemrix-epar-product-information_ro.pdf)

slovenčina (SK) (1.27 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/sk/documents/product-information/pandemrix-epar-product-information_sk.pdf)

slovenščina (SL) (1.19 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/sl/documents/product-information/pandemrix-epar-product-information_sl.pdf)

Suomi (FI) (1.19 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/fi/documents/product-information/pandemrix-epar-product-information_fi.pdf)

svenska (SV) (1.47 MB - PDF)

**First published:**

23/12/2009

**Last updated:**

10/06/2016

[View](/sv/documents/product-information/pandemrix-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0079 28/04/2016

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pandemrix : EPAR - All Authorised presentations

English (EN) (472.78 KB - PDF)

**First published:** 01/10/2009

**Last updated:** 27/10/2015

[View](/en/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-544)

български (BG) (589.98 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/bg/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_bg.pdf)

español (ES) (515.28 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/es/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_es.pdf)

čeština (CS) (578.21 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/cs/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (516.06 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/da/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (472.76 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/de/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (473.26 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/et/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (593.22 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/el/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_el.pdf)

français (FR) (514.55 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/fr/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (513.09 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/it/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (578.43 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/lv/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (556.74 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/lt/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (582.28 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/hu/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (580.98 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/mt/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (472.76 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/nl/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_nl.pdf)

polski (PL) (572.59 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/pl/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_pl.pdf)

português (PT) (518.31 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/pt/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_pt.pdf)

română (RO) (562.05 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/ro/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (576.85 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/sk/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (485.18 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/sl/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (464.32 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/fi/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (476.27 KB - PDF)

**First published:**

01/10/2009

**Last updated:**

27/10/2015

[View](/sv/documents/all-authorised-presentations/pandemrix-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pandemrix Active substance split influenza virus inactivated, containing antigen equivalent to A/California/07/2009 (H1N1)-derived strain used NYMC X-179A International non-proprietary name (INN) or common name influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted) Therapeutic area (MeSH)

- Influenza, Human
- Immunization
- Disease Outbreaks

Anatomical therapeutic chemical (ATC) code J07BB02

### Pharmacotherapeutic group

Influenza vaccines

### Therapeutic indication

Prophylaxis of influenza caused by A (H1N1)v 2009 virus. Pandemrix should only be used if the recommended annual seasonal trivalent / quadrivalent influenza vaccines are not available and if immunisation against (H1N1)v is considered necessary (see sections 4.4 and 4.8).

Pandemrix should be used in accordance with Official Guidance.

## Authorisation details

EMA product number EMEA/H/C/000832 Marketing authorisation holder

GlaxoSmithKline Biologicals S.A.

Rue de l'Institut, 89

Marketing authorisation issued 20/05/2008 Expiry of marketing authorisation 13/08/2015 Revision 23

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pandemrix : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (210.28 KB - PDF)

**First published:** 04/12/2009

**Last updated:** 10/06/2016

[View](/en/documents/procedural-steps-after/pandemrix-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Pandemrix-H-C-832-II-0079 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/566359/2015

English (EN) (3.42 MB - PDF)

**First published:** 10/06/2016

**Last updated:** 10/06/2016

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0079-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-P46-0102-0103 : EPAR - Assessment Report

Adopted

Reference Number: EMA/180287/2015

English (EN) (2.49 MB - PDF)

**First published:** 17/03/2015

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-p46-0102-0103-epar-assessment-report_en.pdf)

Pandemrix-H-C-832-P46-0099 : EPAR - Assessment Report

Adopted

Reference Number: EMA/180225/2015

English (EN) (672.8 KB - PDF)

**First published:** 17/03/2015

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-p46-0099-epar-assessment-report_en.pdf)

Pandemrix-H-C-832-II-0069 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/521070/2014

English (EN) (1.22 MB - PDF)

**First published:** 08/10/2014

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0069-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-II-0061 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/691037/2013

English (EN) (1.5 MB - PDF)

**First published:** 09/12/2013

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0061-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-A20-0045 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/873244/2011

English (EN) (837.01 KB - PDF)

**First published:** 25/11/2011

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-a20-0045-epar-assessment-report-article-20_en.pdf)

Pandemrix-H-C-832-II-0052 : EPAR - Assessment Report - Variation

Adopted

English (EN) (907.88 KB - PDF)

**First published:** 25/11/2011

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0052-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-II-0051 : EPAR - Assessment Report - Variation

Adopted

English (EN) (910.71 KB - PDF)

**First published:** 25/11/2011

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0051-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-II-0048: EPAR - Assessment Report - Variation

Adopted

English (EN) (990.93 KB - PDF)

**First published:** 25/07/2011

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0048-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-II-0046 : EPAR - Assessment Report - Variation

Adopted

English (EN) (1.02 MB - PDF)

**First published:** 25/07/2011

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0046-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-SW-0041 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/508065/2010

English (EN) (937.3 KB - PDF)

**First published:** 04/10/2010

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-sw-0041-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-II-0033 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/95394/2010

English (EN) (1.54 MB - PDF)

**First published:** 04/03/2010

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0033-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-II-0034 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/842790/2009

English (EN) (773.43 KB - PDF)

**First published:** 23/12/2009

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0034-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-II-0028 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/815870/2009

English (EN) (850.31 KB - PDF)

**First published:** 23/12/2009

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0028-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-II-0032 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/842769/2009

English (EN) (765.38 KB - PDF)

**First published:** 23/12/2009

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0032-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-II-0023 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMEA/CHMP/763804/2009

English (EN) (640.06 KB - PDF)

**First published:** 04/12/2009

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0023-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-II-0024 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMEA/CHMP/763919/2009

English (EN) (575.62 KB - PDF)

**First published:** 04/12/2009

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0024-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-II-0025 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMEA/CHMP/763933/2009

English (EN) (1.61 MB - PDF)

**First published:** 04/12/2009

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0025-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-II-0026 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMEA/CHMP/763956/2009

English (EN) (518.55 KB - PDF)

**First published:** 04/12/2009

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0026-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-II-0019 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMEA/CHMP/667130/2009

English (EN) (676.51 KB - PDF)

**First published:** 16/11/2009

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0019-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-PU-0017 : EPAR - Assessment Report - Variation

Reference Number: EMEA/CHMP/619109/2009

English (EN) (1.76 MB - PDF)

**First published:** 02/10/2009

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-pu-0017-epar-assessment-report-variation_en.pdf)

Pandemrix-H-C-832-II-0005 : EPAR - Assessment Report - Variation

Reference Number: EMEA/CHMP/352183/2009

English (EN) (909.87 KB - PDF)

**First published:** 14/08/2009

**Last updated:** 27/10/2015

[View](/en/documents/variation-report/pandemrix-h-c-832-ii-0005-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Pandemrix : EPAR - Public assessment report

English (EN) (1.04 MB - PDF)

**First published:** 03/06/2008

**Last updated:** 27/10/2015

[View](/en/documents/assessment-report/pandemrix-epar-public-assessment-report_en.pdf)

#### News on Pandemrix

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2012) 19/10/2012

[European Medicines Agency reviews hypothesis on Pandemrix and development of narcolepsy](/en/news/european-medicines-agency-reviews-hypothesis-pandemrix-development-narcolepsy) 19/10/2012

[European Medicines Agency recommends restricting use of Pandemrix](/en/news/european-medicines-agency-recommends-restricting-use-pandemrix) 21/07/2011

[European Medicines Agency recommends interim measures for Pandemrix](/en/news/european-medicines-agency-recommends-interim-measures-pandemrix) 15/04/2011

[European Medicines Agency reviews further data on narcolepsy and possible association with Pandemrix](/en/news/european-medicines-agency-reviews-further-data-narcolepsy-possible-association-pandemrix) 18/02/2011

[European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy](/en/news/european-medicines-agency-updates-review-pandemrix-reports-narcolepsy) 23/09/2010

[CHMP meets to discuss Avandia and Pandemrix](/en/news/chmp-meets-discuss-avandia-pandemrix) 08/09/2010

[CHMP meeting on 8 September 2010 to discuss Avandia and Pandemrix](/en/news/chmp-meeting-8-september-2010-discuss-avandia-pandemrix) 03/09/2010

[European Medicines Agency starts review of Pandemrix](/en/news/european-medicines-agency-starts-review-pandemrix) 27/08/2010

[European Medicines Agency updates on pandemic influenza](/en/news/european-medicines-agency-updates-pandemic-influenza-0) 22/01/2010

[European Medicines Agency advises of risk of fever in young children following vaccination with Pandemrix](/en/news/european-medicines-agency-advises-risk-fever-young-children-following-vaccination-pandemrix) 04/12/2009

[European Medicines Agency reaffirms efficacy and safety of H1N1 pandemic vaccines](/en/news/european-medicines-agency-reaffirms-efficacy-safety-h1n1-pandemic-vaccines) 20/11/2009

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 16-19 November 2009](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-november-2009) 20/11/2009

[European Medicines Agency recommends authorisation of two vaccines for influenza pandemic (H1N1) 2009](/en/news/european-medicines-agency-recommends-authorisation-two-vaccines-influenza-pandemic-h1n1-2009) 25/09/2009

#### More information on Pandemrix

- [Article 5(3) opinion: Hypothesis on Pandemrix and development of narcolepsy](/en/human-regulatory-overview/post-authorisation/referral-procedures-human-medicines/article-53-opinions-any-scientific-matter-human-medicines)

#### More information on Pandemrix

- [EMEA-000725-PIP01-09-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000725-pip01-09-m03)
- [116602 - Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix in the United Kingdom - post-authorisation study](https://catalogues.ema.europa.eu/study/31677)

**This page was last updated on** 10/06/2016

## Share this page

[Back to top](#main-content)